



Interim report for Bactiguard Holding AB (publ)

Corporate registration number 556822-1187

Second Quarter (April-June 2015)

- During the second quarter, a total of approx. 58,000 (44,000) BIP products were delivered.
- Revenues amounted to SEK 27.7 (31.2) million.
- EBITDA amounted to SEK -10.0 (2.2) million. Provisions for severance pay to the former CEO as well as for doubtful accounts receivable have negatively affected EBITDA during the quarter by SEK -6.6 million. Adjusted for these items, EBITDA amounted to SEK -3.4 million. The provisions for doubtful accounts receivable have no effect on cash flow.
- Reported net profit for the quarter amounted to SEK -11.8 (-44.1) million, corresponding to SEK -0.35 (-2.04) per share. Net profit for the quarter has been positively affected by market valuation of the bond with SEK 11.0 million (-15.2 million). This effect is of an accounting nature, and has no effect on cash flow.
- Operating cash flow for the quarter amounted to SEK -7.8 (-8.3) million, corresponding to SEK -0.23 (-0.39) per share

First half year (January-June 2015)

- During the period, a total of approx. 63,000 (60,000) BIP products were delivered.
- Revenues for the period amounted to SEK 56.6 (65.7) million.
- EBITDA for the period amounted to SEK -36.8 (12.0) million. Provisions and non-recurring costs have negatively affected EBITDA during the period by SEK -35.4 million. Adjusted for these items, EBITDA amounted to SEK -1.4 million. The provisions for doubtful accounts receivable of net SEK -25.5 million have no effect on cash flow.
- Reported net profit for the period amounted to SEK -42.4 (-63.7) million, corresponding to SEK -1.27 (-3.06) per share. Net profit for the period has been positively affected by market valuation of the bond with SEK 17.9 million (-24.2 million).
- Operating cash flow amounted to SEK -16.4 (9.4) million, corresponding to SEK -0.49 (0.45) per share

Key events during the second quarter

- Deliveries to Southern Africa and Saudi Arabia
- Distribution agreement for Israel
- Christian Kinch appointed new CEO
- Stanley Brodén new Chairman

Key events after the end of the second quarter

- Additional order from C.R. Bard

Key figures	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Full year 2014
Revenues, SEKm	27,7	31,2	56,6	65,7	118,9
EBITDA, SEKm	-10,0	2,2	-36,8	12,0	10,3
EBITDA margin, %	-36%	7%	-65%	18%	9%
EBITDA*, SEKm	-10,0	5,2	-36,8	15,0	13,3
EBITDA margin*, %	-36%	17%	-65%	23%	11%
Operating profit, SEKm	-18,2	-5,2	-53,1	-2,8	-19,8
Net profit for the period, SEKm	-11,8	-44,1	-42,4	-63,7	-95,0
Operating cash flow**, SEKm	-7,8	-8,3	-16,4	9,4	-54,0
Earnings per share***, SEK	-0,35	-2,04	-1,27	-3,06	-3,80
Op. cash flow per share****, SEK	-0,23	-0,39	-0,49	0,45	-2,16
Equity ratio, %	64%	58%	64%	58%	64%
Net debt, SEKm	88,5	22,5	88,5	22,5	90,4
Number of shares at the end of period*****	33 302 373	33 302 373	33 302 373	33 302 373	33 302 373
Weighted average number of shares*****	33 302 373	21 573 174	33 302 373	20 790 933	25 007 242

*EBITDA 2014 adjusted for IPO costs

**Cash flow from operating activities after investments and changes in working capital

***Net profit for the period / Weighted average number of shares during the period, issue-adjusted

****Operating cash flow / Weighted average number of shares during the period, issue-adjusted

*****Adjusted for split

Comments by the CEO

At the beginning of June, I once again assumed the role as CEO of Bactiguard after almost one and a half years as Chairman of the Board. At the same time, Stanley Brodén was appointed new Chairman of the Board. The main focus for me and the other members of management is to secure stability and continuity in the company and open up new growth possibilities for Bactiguard, both internationally and in our home market.

Our strategy remains the same. We focus our resources on growth markets where we see the greatest potential and work to secure access to these markets. At the same time, we initiate well defined, complementary studies to strengthen our clinical evidence. We continue to invest in our sales and marketing organization to generate more sales and increase revenues. In addition to this, we will allocate more resources to developing future license businesses, to complement the stable base we have in the long term and successful license agreement we have with C.R. Bard.

During the second quarter, we had a positive volume development in our own BIP portfolio and reported the highest deliveries since the fourth quarter 2013, which is encouraging. The reasons behind this positive development were primarily major deliveries to southern Africa and Saudi Arabia, but Switzerland, Sweden and Iran have also contributed.

That deliveries to Saudi Arabia are increasing is encouraging for several reasons. These are repeat orders from one of our most well established markets and this major delivery means that the previously agreed market contribution has now been consumed. This means that Saudi Arabia can be added to the handful markets that currently generate sales revenues in connection with product deliveries.

Another positive development is that we have made a breakthrough in the Swedish market, as a number of hospitals are initiating trials with our products for infection control. At the same time, a couple of regions have introduced a special category for infection control in their tenders. This bodes well for the future.

In terms of revenues and results, the second quarter was not as strong as the corresponding quarter 2014. This was primarily due to the lack of income from territorial fees this quarter. This is related to the fact that we focus on initiating marketing activities and product deliveries as soon as possible when signing new distribution contracts, which means that we report revenues when product deliveries are made. We have continued the review of our distribution network and concluded that we need to change distributor in a handful markets. In connection with this review, we have made reservations for doubtful accounts receivable. Results were also affected by severance pay to the former CEO.

After the end of the quarter, we received a major one off order from C.R. Bard, intended to increase their safety stock of Bactiguard-coated Foleys for infection control. The order will generate additional sales of approximately SEK 28 million in the third quarter and make a positive contribution to cash flow, which is very encouraging. This has a positive effect on total sales to Bard this year but it is worth mentioning that we do not expect the underlying volume to be affected.

Looking ahead, the intensified negotiations which have been ongoing in Iraq for some time are still in their final stages, but the process has been delayed by the political turmoil in the country in the past few weeks. In India we are initiating clinical studies and continue the work of establishing sales channels. The import license for Mexico has been secured and market activities will be initiated shortly. We are still waiting for the final product approval in China, a process which is slowly moving forward.

At the annual general meeting in May, the healthcare related competence of the Board was strengthened by the election of Stanley Brodén, former CEO of Aleris and previously employed by Capio, two of the most prominent private healthcare providers in Sweden and Peter Hentschel, who has extensive international experience from the medical device industry, primarily from Mölnlycke. I am convinced that they will contribute to Bactiguard's development in a very concrete way and look forward to advancing our position in the global market for infection control, together with the other members of the management team and all Bactiguard employees.

Christian Kinch
VD

Key events during the second quarter

Delivery to Southern Africa

In April 2015, Bactiguard delivered an order of some 20 000 products for infection control to Southern Africa, comprising both Foley and central venous catheters for the healthcare system in Angola. The delivery was made against market contribution, and will therefore not generate any new revenue.

Delivery to Saudi Arabia

At the end of June 2015, Bactiguard delivered an order of more than 20 000 Foley catheters to Gulf Medical in Saudi Arabia. Part of the delivery to Saudi Arabia has generated direct sales revenues in the second quarter. From the third quarter, all deliveries to Saudi Arabia will generate direct sales revenues.

Gulf Medical distributes Bactiguard's portfolio of products for infection control to the healthcare system in both Saudi Arabia and the United Arab Emirates (UAE).

Bactiguard enters distribution agreement for Israel

Bactiguard has entered an exclusive distribution agreement for Israel with Dover Medical & Scientific Equipment Ltd. The agreement covers sales of all products in the Bactiguard Infection Protection portfolio for the healthcare system. The market strategy for Israel will now change from direct sales to sales via a distributor.

CEO Niels Christiansen leaves Bactiguard

In June, Niels Christiansen left his position as CEO of Bactiguard Holding AB (publ). The Board appointed Christian Kinch as new CEO. Stanley Brodén was appointed Chairman of the Board until the Annual General Meeting (AGM) in 2016.

Key events after the end of the second quarter

Additional order from C.R. Bard

Bactiguard has received a major one off order from C.R. Bard (Bard) intended to increase their safety stock of infection prevention catheters. The order will generate additional sales of approximately SEK 28 million in the third quarter and make a positive contribution to cash flow.

The additional order will lead to higher total sales to Bard for 2015 compared to last year. Excluding this order, the underlying volume of coating concentrate delivered to Bard in 2015 is not expected to be affected.

Consolidated revenues and earnings

Revenues

Bactiguard has three revenue streams:

Sales of BIP products

The BIP portfolio currently includes sales of the BIP Foley, BIP ETT and BIP CVC products.

License revenues

License revenues are attributable to sales of products under license, which currently includes the group's licensing agreement with C.R. Bard, Inc. (Bard) regarding Foley catheters for the USA, Japan, the UK, Ireland, Canada and Australia.

Territorial fees

Territorial fees are attributable to the compensation received when entering into a contract with a distributor that obtains exclusive rights to sell Bactiguard's products on a distinct geographical market.

Other revenue

Comprises mainly foreign exchange differences and any other operating income.

Bactiguard's BIP (Bactiguard Infection Protection) product portfolio includes medical devices in three areas: urinary tract, respiratory tract and blood streams.

BIP Foley	BIP ETT	BIP CVC
 <ul style="list-style-type: none">BIP Foley is the company's urinary catheter, which uses the Bactiguard coating to reduce the risk of patients contracting catheter-associated infections of the urinary tract.	 <ul style="list-style-type: none">BIP ETT is the company's endotracheal tube, which uses the Bactiguard coating intended to reduce the risk of patients contracting ventilator-associated pneumonia.	 <ul style="list-style-type: none">BIP CVC is the company's central venous catheter, which uses the Bactiguard coating to reduce the risk of patients contracting catheter-associated blood infections.

Revenue distribution

Second quarter (April-June)


Consolidated revenues for the second quarter amounted to SEK 27.7 (31.2) million, which is a decrease of approx. 11 % compared to the same quarter last year. The decrease is related to lower revenues from Territorial fees, which were non-existent during the second quarter 2015. During the quarter a new distribution agreement for Israel was signed. The agreement does not include any Territorial fees and thus generates direct sales revenues (Sales of BIP Products) upon product deliveries.

The bulk of revenues during the first quarter (93 %) came from License revenues. The total volumes to Bard was 3 % lower compared to the same quarter last year, which was due to acceleration of orders during June 2014. A positive currency effect of approx. SEK 5.7 (0.1) million however meant that License revenues in the second quarter 2015 increased by approx. 13 % to SEK 25.8 (22.8) million.

Sales of BIP products amounted to 3.7 % of revenues (approx. SEK 1 million) in the second quarter, with sales to Saudi Arabia, Iran, Switzerland, Aland Islands and Sweden. Sales revenue from Saudi Arabia reflect a breakthrough, since these are the first recorded sales revenues from a distributor (Gulf Medical) where the previously agreed market contribution has been fully consumed. Part of the delivery to Saudi Arabia has thereby generated direct sales revenues ("Sales of BIP products") in the second quarter. From the third quarter, all deliveries to Saudi Arabia will generate direct sales revenues.

Other product shipments have resulted from product deliveries to distributors against market contribution, and therefore have not generated revenue during the quarter.

Other revenues during the quarter (3.2 %) are attributable to exchange rate differences and EU grants for development projects.




First half year (January-June)

Consolidated revenues for the first half year amounted to SEK 56.6 (65.7) million, a decrease of approx. 14 % compared to the first half year 2014. The bulk of the revenue 93 % (69 %), was attributable to license revenues. A positive currency effect on License revenues amounted to approx. SEK 11.0 (0.3) million.

	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Full year 2014
License revenues	93,1%	73,1%	93,0%	69,0%	75,5%
Territorial fees	0,0%	15,4%	0,0%	24,9%	14,4%
Sales of BIP products	3,7%	4,7%	2,0%	2,3%	1,8%
Other revenue	3,2%	6,8%	5,0%	3,7%	8,3%

Product deliveries



During the second quarter 2015, a total of approx. 58,000 BIP products were delivered, compared to approx. 44,000 in the corresponding period of 2014, an increase of approx. 32 %. This includes major deliveries to South Africa and Saudi Arabia, but also Switzerland, Sweden and Iran have contributed.

During the first half year 2015, a total of approx. 63,000 products were delivered, compared to approx. 60.000 in the corresponding period of 2014, an increase of approx. 5 %.

Financial results

Second quarter (April-June)

EBITDA for the second quarter amounted to SEK -10.0 (2.2) million. Provisions have negatively affected EBITDA during the quarter by SEK -6.6 million. Adjusted for these items, EBITDA amounted to SEK -3.4 million. The change compared with the corresponding period last year is mainly a result of the implemented provisions and lower revenues from Territorial fees.

Consolidated operating profit for the second quarter of 2015 amounted to SEK -18.2 (-5.2) million. In Other external expenses a provision for doubtful accounts receivable for Ukraine, Malaysia, Qatar and South Africa, is included with net SEK 2 million. The provision regarding Ukraine is a consequence of the current market situation in the country, while the other provisions are a result of malfunctioning distributors where Bactiguard will change to new distributors. Personnel expenses include a provision for severance pay to the former CEO of SEK 4.6 million.

Financial items for the quarter amounted to SEK 5.0 (-40.1) million. The effects of market valuation of the bond loan, which have no effect on cash flow, are recognised as financial items in the income statement. During the second quarter of 2015, the market valuation of the bond affected financial items positively by SEK 11.0 (-15.2) million. Interest expense related to the bond amounted to SEK -5.0 (-11.3) million in the second quarter. The lower interest expense reflects the fact that the outstanding bond loan decreased from an initial nominal value of SEK 450 million to a nominal value of SEK 183.5 million through the set-off issue completed in connection with the listing of the company's shares on Nasdaq Stockholm and through repurchase of bonds in the market, see Financial Position below.

Consolidated net profit for the second quarter amounted to SEK -11.8 (-44.1) million where the effect from market valuation of the bond loan and costs related to the IPO during the second quarter of 2014, are the main reasons behind the positive change in net profit.

First half year (January-June)

EBITDA for the first half year amounted to SEK -36.8 (12.0) million. Provisions and non-recurring costs have negatively affected EBITDA during the period by SEK -35.4 million. Adjusted for these items, EBITDA amounted to SEK -1.4 million. The provisions for doubtful account receivables of net SEK -25.5 million have no effect on the cash flow.

Consolidated net profit for the first half year amounted to SEK -42.4 (-63.7) million. Net profit is next to the above provisions and non-recurring costs also affected by the market valuation of the bond of SEK 17.9 (-24.2) million.

Cash flow

Second quarter (April-June)

Operating cash flow (cash flow from operating activities after investments and changes in working capital) for the second quarter amounted to SEK -7.8 (-8.3) million. Cash flow from changes in working capital made a positive contribution with SEK 3.3 (3.6) million but was burdened by a negative contribution from Cash flow from operating activities with SEK -8.1 (-10.2) million. The implemented provisions for doubtful accounts receivables had no cash effect. The severance pay to the former CEO will be paid continuously for one year as of June 12 2015.

Since no activities were conducted in Cash flow from financing activities during the quarter, the total cash flow for the second quarter is the same amount as the Operating cash flow.

First half year (January-June)

Operating cash flow for the first half year 2015 amounted to SEK -16.4 (9.4) Mkr.

Total cash flow for the first half year was SEK -21.6 (230.1) million. Of this, repurchase of bonds amounted to SEK 5.2 million (corresponding to a nominal value of SEK 5 million).

Investments

Investments in property, plant and equipment during the second quarter amounted to SEK 2.2 (1.1) million, mainly related to the new integrated headquarters and production facility. Investment in intangible assets, mainly related to capitalized development costs, amounted to SEK 0.8 (0.7) million for the period. No investments were made in financial non-current assets during the period (-).

Financial position

The consolidated equity ratio was 64 % at 30 June 2015 (64 % at 31 December 2014) and equity amounted to SEK 476.3 (518.7 at 31 December 2014) million.

Bactiguard has a bond loan that matures on 12 December 2016, with an annual coupon of 11 %, payable in December each year. After completion of the set-off issue in connection with the listing of the company's shares on Nasdaq Stockholm in 2014, when holders of bonds with a total nominal value of SEK 222.5 million chose to offset bonds against shares, the nominal value of the outstanding bond loan was SEK 227.5 million. Subsequently, bonds have been repurchased in the market, which further has reduced the outstanding nominal value.

The bond is listed on Nasdaq Stockholm. During the first quarter, Bactiguard repurchased bonds with a total nominal value of SEK 5 million. During the second quarter, no repurchases have been completed. Along with the repurchases conducted during the third and fourth quarter of 2014, the total nominal value of the repurchased bonds amounted to SEK 44.0 million. The nominal value of the outstanding bond loan after completed repurchases is thereby SEK 183.5 million.

The bond is valued at market value and on 30 June 2015, net outstanding bond (nominal value SEK 183.5 million) was valued at SEK 172.5 million (price 94.0, which is a decrease from 100.0 at the end of the first quarter 2015).

Consolidated cash position at 30 June 2015 amounted to SEK 84.0 million. Net debt amounted to SEK 88.5 million (SEK 90.4 million at 31 December 2014).

The total assets of the group at 30 June 2015 amounted to SEK 745.0 million (811.1 million at 31 December 2014). The largest asset item in the balance sheet is technology related to Bactiguard's product portfolio, which at 30 June amounted to SEK 272.3 million (284.2 million at 31 December 2014).

Accounts receivable (short- and long term) amounted to SEK 56.1 million at 30 June 2015, which is a decrease of SEK 35.1 million since 31 December 2014. The decrease can be explained by payments on existing accounts receivables as well as provisions for doubtful account receivables during the first half year.

Other disclosures

The share and share capital

Trade in the Bactiguard share takes place on Nasdaq Stockholm under the ticker symbol "BACTI". The last price paid for the listed B share at 30 June 2015 was SEK 10.00, and the market capitalization amounted to SEK 333 million.

The share capital of Bactiguard at 30 June 2015 amounted to SEK 0.8 million divided into 29,302,373 B shares, each with one vote (29,302,373 votes) and 4,000,000 A shares, each with ten votes (40,000,000 votes). The total number of shares and votes in Bactiguard at 30 June 2015 amounted to 33,302,373 shares and 69,302,373 votes.

Ownership

At 30 June 2015, Bactiguard had 2,749 shareholders.

Shareholders	No. of A shares	No. of B shares	Total number	% of capital	% of votes
CHRISTIAN KINCH WITH FAMILY AND COMPANY	2 000 000	8 160 484	10 160 484	30,5%	40,6%
THOMAS VON KOCH WITH COMPANY	2 000 000	8 160 384	10 160 384	30,5%	40,6%
HANDELSBANKEN FONDER AB		1 012 828	1 012 828	3,0%	1,5%
ROBUR FÖRSÄKRING		889 571	889 571	2,7%	1,3%
STÅHLBERG, JAN		582 544	582 544	1,8%	0,8%
FRÖAFALL INVEST AB		516 000	516 000	1,6%	0,7%
LÄNSFÖRSÄKRINGAR JÖNKÖPING		474 377	474 377	1,4%	0,7%
NORDNET PENSIONS FÖRSÄKRING AB		466 071	466 071	1,4%	0,7%
SARGAS EQUITY AB		364 090	364 090	1,1%	0,5%
NORTAL CAPITAL AB		246 200	246 200	0,7%	0,4%
Total, major shareholders	4 000 000	20 872 549	24 872 549	74,7%	87,8%
Total, others	0	8 429 824	8 429 824	25,3%	12,2%
Total number of shares	4 000 000	29 302 373	33 302 373	100%	100%

Human resources

The average number of employees in the group in the period January to June 2015 amounted to 66 (56), of which 37 (30) women.

Accounting and valuation principles

The consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS). The interim report has been prepared in accordance with IAS 34 Interim Reporting and the Annual Accounts Act. The parent company financial statements have been prepared in accordance with the Annual Accounts Act and the Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities.

The accounting and valuation principles are unchanged from those applied in the Annual Report 2014. New standards effective from 1 January 2015 have had no material impact on the group. The new and amended standards and interpretations that have been issued but is effective for fiscal years beginning after 1 January, 2016 have not yet been applied by the Group.

Financial assets and financial liabilities measured at fair value in the balance sheet are classified into one of three levels based on the information used to determine fair value. Bactiguard bond loan is valued using level 1, is listed on Nasdaq Stockholm and is valued at quoted price.

Segment reporting

An operating segment is a component of an entity that engages in business activities from which it may derive revenues and incur expenses, whose operating results are regularly reviewed by the chief operating decision maker and for which there is discrete financial information. The company's reporting of operating segments is consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function that assesses the operating segment performance and decides how to allocate resources. The company has determined that the group executive management constitutes the chief operating decision maker.

The company is considered in its entirety to operate within one business segment.

Related-party transactions

Transactions between the company and its subsidiaries, which are related parties to the company, have been eliminated on consolidation.

Services and other transactions between companies within the group are charged according to commercial principles. Main shareholders Christian Kinch and Thomas von Koch have entered into guarantee commitments for Bactiguard AB's commitments to Samhall AB.

Other than as described above, neither Bactiguard nor its subsidiaries have granted loans, guarantees or sureties to, or for the benefit of, any directors or senior managers of the group. None of these persons has any direct or indirect participation in any other business transaction with any entity of the group which is, or was, unusual in its nature or with regard to its terms.

Parent company

Revenues consist of invoiced intercompany expenses (management fees). During the period the parent company received interest on its receivables from group companies. Company costs primarily relate to financial expenses of which the interest due on the bond loan is the single largest item. No investments were made during the period.

Risk factors

Companies within the group are exposed to various types of risk through their activities. The company continually engages in a process of identifying all risks that may arise and assessing how each of these risks shall be managed. The group's goal is to create an overall risk management programme that focuses on minimising potential adverse effects on the company's financial results. The company is primarily exposed to market related risks, operational risks and financial risks. A description of these risks can be found on page 21 and 38-40 of the Annual Report for 2014.

Financial targets

Bactiguard aims to create value and provide a good return for shareholders. One financial target is to grow by at least 30 % on average per year over the next five years. Further, to achieve an EBITDA margin of at least 30 % on an annual basis, with the aim of reaching 40 %. Bactiguard will continue to grow the business by strengthening its sales and marketing organization, developing products that complement the existing BIP portfolio and by entering into more licensing agreements. Bactiguard also aims to sign two to three new licensing agreements over the next five years.

Another financial target is to have an equity ratio of 30-50 %, and a long-term objective is for a dividend of 30-50 % of profit after tax. The company is in an expansion phase and will therefore prioritise growth over dividends in the coming years.

Condensed consolidated income statement

Amounts in TSEK	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Full year 2014
<i>Revenues</i>					
License revenues	25 820	22 828	52 610	45 352	89 779
Territorial fees	-	4 814	-	16 401	17 108
Sales of BIP products	1 023	1 455	1 121	1 525	2 160
Other revenue	890	2 139	2 836	2 460	9 811
	27 733	31 236	56 567	65 738	118 857
<i>Raw materials and consumables</i>					
Raw materials and consumables	-1 886	-1 590	-3 384	-3 196	-6 102
Other external expenses	-14 806	-15 183	-55 005	-27 283	-54 187
Personnel costs	-18 469	-11 542	-30 672	-22 315	-44 996
Depreciation and amortisation	-8 155	-7 422	-16 264	-14 851	-30 131
Other operating expenses	-2 583	-733	-4 329	-922	-3 229
	-45 899	-36 470	-109 654	-68 567	-138 646
Operating profit	-18 166	-5 234	-53 087	-2 829	-19 788
<i>Financial items</i>					
Financial income	11 100	910	18 527	940	3 641
Financial expenses	-6 139	-41 020	-10 431	-64 215	-83 999
	4 961	-40 110	8 096	-63 275	-80 358
Profit before tax	-13 205	-45 344	-44 991	-66 104	-100 146
Tax for the period	1 388	1 262	2 561	2 431	5 104
Net profit/loss for the period	-11 817	-44 082	-42 430	-63 673	-95 042
Attributable to:					
Shareholders of the parent	-11 817	-44 082	-42 430	-63 673	-95 042
Earnings per share, SEK*	-0,35	-2,04	-1,27	-3,06	-3,80

Condensed consolidated statement of comprehensive income

Amounts in TSEK	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Full year 2014
Net profit/loss for the period	-11 817	-44 082	-42 430	-63 673	-95 042
<i>Other comprehensive income:</i>					
<u>Items that will not be reclassified to profit or loss for the year</u>	-	-	-	-	-
<u>Items that will be reclassified to profit or loss for the year</u>					
Translation differences	609	-363	66	-159	-655
Other comprehensive income, after tax	609	-363	66	-159	-655
Total comprehensive income for the period	-11 208	-44 445	-42 364	-63 832	-95 697
Attributable to:					
Shareholders of the parent	-11 208	-44 445	-42 364	-63 832	-95 697
Total earnings per share, SEK*	-0,34	-2,06	-1,27	-3,07	-3,83
Number of shares at the end of period ('000)	33 302	33 302	33 302	33 302	33 302
Weighted average number of shares ('000)	33 302	21 573	33 302	20 791	25 007

* no dilution effect

Condensed consolidated statement of financial position

Amounts in TSEK	2015-06-30	2014-06-30	2014-12-31
ASSETS			
Non-current assets			
Goodwill	226 292	226 292	226 292
Technology	272 321	296 128	284 225
Brands	25 572	25 572	25 572
Customer relationships	13 498	14 678	14 088
Capitalised development expenditure	8 464	7 784	7 772
Patents	1 226	1 469	1 454
Intangible assets	547 373	571 923	559 402
Improvements, leasehold	17 410	12 207	15 812
Machinery and other technical plant	9 154	6 293	9 763
Equipment, tools and installations	6 182	1 934	6 204
Property, plant and equipment	32 746	20 434	31 779
Accounts receivable	7 962	-	9 531
Investments in associates	1 368	1 293	1 368
Financial assets	9 330	1 293	10 899
Total non-current assets	589 449	593 650	602 080
Current assets			
Inventory	10 422	6 524	8 974
Accounts receivable	48 098	94 276	81 625
Other current receivables	12 982	15 093	13 303
Cash and cash equivalents	84 034	235 062	105 147
Total current assets	155 536	350 955	209 049
TOTAL ASSETS	744 985	944 605	811 128
Equity attributable to shareholders of the parent			
Share capital	833	833	833
Other equity	475 512	548 633	517 877
Total equity	476 345	549 466	518 710
Non-current liabilities			
Bonds	172 490	229 206	195 569
Deferred tax liability	36 677	41 947	39 237
	209 167	271 153	234 806
Current liabilities			
Bank overdrafts	0	28 337	0
Accounts payable	6 367	16 774	10 995
Other current liabilities	2 869	3 450	3 938
Accrued expenses and deferred income	50 237	75 425	42 679
	59 473	123 986	57 613
Total liabilities	268 640	395 139	292 418
TOTAL EQUITY AND LIABILITIES	744 985	944 605	811 128

Condensed consolidated statement of changes in equity

Amounts in TSEK	Equity attributable to shareholders of the parent				
	Share capital	Other capital contributions	Translation reserve	Retained earnings including net profit for the period	Total equity
Opening balance, 1 January 2014	500	202 673	-139	-62 082	140 953
Profit/loss for the period	-	-	-	-63 672	-63 672
<i>Other comprehensive income:</i>					
Translation differences	-	-	-159	-	-159
Total comprehensive income after tax	0	0	-159	-63 672	-63 831
Transactions with shareholders					
Share issue	333	471 908	-	-	472 240
Repurchase of options	-	-	-	104	104
Total transactions with shareholders	333	471 908	0	104	472 344
Closing balance, 30 June 2015	833	674 581	-298	-125 650	549 466
Opening balance, 1 January 2015	833	675 690	-794	-157 020	518 709
Profit/loss for the period	-	-	-	-42 430	-42 430
<i>Other comprehensive income:</i>					
Translation differences	-	-	66	-	66
Total comprehensive income after tax	0	0	66	-42 430	-42 364
Transactions with shareholders					
Share issue	-	-	-	-	-
Repurchase of options	-	-	-	-	-
Total transactions with shareholders	0	0	0	0	0
Closing balance, 30 June 2015	833	675 690	-728	-199 450	476 345

Condensed consolidated statement of cash flows

Amounts in TSEK	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Full year 2014
Cash flow from operating activities					
Net profit/loss for the period	-11 817	-44 082	-42 430	-63 672	-95 042
Accrued interest expense	5 047	6 256	10 203	12 513	-1 725
Adjustments for depreciation and amortisation and other non-cash items	-1 349	27 676	20 900	48 855	53 904
	-8 119	-10 150	-11 327	-2 305	-42 863
Cash flow from changes in working capital					
Increase/decrease inventory	1 391	-1 875	-1 403	-2 836	-5 936
Increase/decrease accounts receivable	250	-9 026	226	-158	2 982
Increase/decrease other current receivables	2 206	-5 623	2 347	-5 198	-2 270
Increase/decrease accounts payable	-5 294	9 100	-6 751	9 369	3 561
Increase/decrease other current liabilities	4 763	11 013	5 748	14 582	8 782
	3 316	3 589	166	15 759	7 119
Cash flow from investing activities					
Investments in intangible assets	-784	-688	-1 256	-1 692	-2 397
Investments in property, plant and equipment	-2 171	-1 062	-4 008	-2 344	-15 692
Investments in associates	-	-	-	-	-144
	-2 955	-1 750	-5 264	-4 036	-18 233
Operating cash flow	-7 758	-8 311	-16 425	9 418	-53 976
Cash flow from financing activities					
Share issue	-	472 240	-	472 240	473 350
Amortisation of debt	-	-222 500	-5 150	-222 500	-321 495
Borrowings/loans granted/overdrafts	-	-28 937	-	-29 124	-
Repurchase of options	-	-	-	104	104
	0	220 803	-5 150	220 720	151 959
Cash flow for the period	-7 758	212 492	-21 575	230 138	97 983
Cash and cash equivalents at start of period	91 851	23 205	105 147	5 417	5 417
Exchange difference in cash and cash equivalents	-59	-635	462	-493	1 747
Cash and cash equivalents at end of period	84 034	235 062	84 034	235 062	105 147

Condensed parent company income statement

Amounts in TSEK	Apr-Jun 2015	Apr-Jun 2014	Jan-Jun 2015	Jan-Jun 2014	Full year 2014
Revenues	2 753	3 115	4 981	5 920	12 287
	2 753	3 115	4 981	5 920	12 287
Operating expenses	-8 629	-6 885	-11 556	-10 144	-18 604
	-8 629	-6 885	-11 556	-10 144	-18 604
Operating profit/loss	-5 876	-3 770	-6 575	-4 224	-6 317
Net financial items	-5 519	-24 566	-10 879	-36 298	-46 713
Profit/loss after financial items	-11 395	-28 336	-17 454	-40 522	-53 030
Tax for the period	-	-	-	-	-
Net profit/loss for the period	-11 395	-28 336	-17 454	-40 522	-53 030

Condensed parent company statement of comprehensive income

The parent company has no items in 2015 or 2014 recognised in other comprehensive income. The period's statements for the parent company therefore present no separate statement of comprehensive income.

Condensed parent company balance sheet

Amounts in TSEK	2015-06-30	2014-06-30	2014-12-31
ASSETS			
Non-current assets			
Financial assets	666 574	571 574	656 574
Total non-current assets	666 574	571 574	656 574
Current assets			
Receivables from group companies	22 437	2 314	13 407
Prepayments and accrued income	479	1 441	360
Other current receivables	63	1 231	139
Cash and cash equivalents	68 991	228 240	87 319
Total current assets	91 970	233 226	101 225
TOTAL ASSETS	758 544	804 800	757 799
EQUITY & LIABILITIES			
Total equity	511 604	540 456	529 058
Non-current liabilities	224 090	221 751	222 920
Liabilities to group companies	-	-	-
Other liabilities	22 850	42 593	5 820
Current liabilities	22 850	42 593	5 820
Total liabilities	246 940	264 344	228 740
TOTAL EQUITY AND LIABILITIES	758 544	804 800	757 799

Forthcoming disclosures of information

12 November 2015	Interim report, 1 Jul – 30 Sep 2015
February 2016	Year-end report 2015

Contacts

For additional information, please contact:

Christian Kinch, CEO: +46 8 440 58 80

Fredrik Järresten, CFO: +46 725 500 089

Cecilia Edström, Director of Sales, Marketing & Communications: +46 722 262 328

For additional information about Bactiguard's business, please visit the company's website:

www.bactiguard.se

Signatories to the report

The board of directors and the CEO certify that the interim report, to the best of their knowledge, provides a fair overview of the parent company's and the group's operations, financial position and results and describes the material risks and uncertainties faced by the parent company and the companies included in the group.

Stockholm, 13 August 2015

Stanley Brodén

Chairman

Mia Arnhult

Board member

Peter Hentschel

Board member

Christian Kinch

CEO

This interim report is unaudited.

Bactiguard is required to disclose the information in this report under the provisions of the Securities Market Act (SFS 2007:528). The information was submitted for publication on 13 August 2015 at 08.00 CET.